June, 2018 | BMT Reviews, Lymphoma, Multiple Myeloma
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving.
June, 2017 | BMT Reviews, Multiple Myeloma
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
April, 2017 | Infectious Disease, Lymphoma, MDS / Myeloproliferative, Multiple Myeloma, Webinars
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers Sergio A. Giralt, MD Program Chair Professor of Medicine Weill Cornell College of Medicine Chief Attending, Adult BMT Service Memorial...
June, 2016 | BMT Reviews, Multiple Myeloma
In this CME activity, leading experts in multiple myeloma will review changes in the treatment paradigm, optimal patient selection for transplant, and data from recent clinical trials. They will also provide insight into new strategies for individualized management, the role of early versus late transplant, and how to incorporate novel therapies into clinical practice.
May, 2016 | Multiple Myeloma, Webinars
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Chairs Kenneth C. Anderson, MD Kraft Family Professor of Medicine, Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center and...
July, 2014 | BMT Reviews, Multiple Myeloma, Transplantation / Stem Cell
During the last two decades, the treatment of multiple myeloma (MM) has produced significant improvements in overall survival and quality of life. This can be attributed to the use of autologous stem cell transplantation, novel drugs in combination with old drugs, bisphosphonates, improved supportive care, and, importantly, dissemination of knowledge about the disease and treatments through multiple societies and medical centers.
